CN105338982B - 固体药用组合物 - Google Patents

固体药用组合物 Download PDF

Info

Publication number
CN105338982B
CN105338982B CN201480036231.6A CN201480036231A CN105338982B CN 105338982 B CN105338982 B CN 105338982B CN 201480036231 A CN201480036231 A CN 201480036231A CN 105338982 B CN105338982 B CN 105338982B
Authority
CN
China
Prior art keywords
acid
pharmaceutical composition
solid pharmaceutical
mixture
dihydroquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480036231.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105338982A (zh
Inventor
内田浩
花田真隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of CN105338982A publication Critical patent/CN105338982A/zh
Application granted granted Critical
Publication of CN105338982B publication Critical patent/CN105338982B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/20Mixing gases with liquids
    • B01F23/23Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
    • B01F23/235Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids for making foam

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201480036231.6A 2013-04-25 2014-04-24 固体药用组合物 Active CN105338982B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-092171 2013-04-25
JP2013092171 2013-04-25
PCT/JP2014/002308 WO2014174846A1 (ja) 2013-04-25 2014-04-24 固形医薬組成物

Publications (2)

Publication Number Publication Date
CN105338982A CN105338982A (zh) 2016-02-17
CN105338982B true CN105338982B (zh) 2017-10-10

Family

ID=51791434

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480036231.6A Active CN105338982B (zh) 2013-04-25 2014-04-24 固体药用组合物

Country Status (7)

Country Link
US (1) US9603804B2 (enExample)
EP (1) EP2990038B1 (enExample)
JP (2) JP5651812B1 (enExample)
CN (1) CN105338982B (enExample)
CA (1) CA2910112C (enExample)
ES (1) ES2768651T3 (enExample)
WO (1) WO2014174846A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5700740B1 (ja) 2013-04-25 2015-04-15 杏林製薬株式会社 固形医薬組成物
US20170246160A1 (en) * 2014-10-23 2017-08-31 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
JP6018334B2 (ja) * 2014-10-23 2016-11-02 杏林製薬株式会社 固形医薬組成物
CA2988092A1 (en) * 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
JP6031216B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
JP6031217B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
CA2987879A1 (en) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
US10206917B2 (en) 2015-06-02 2019-02-19 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
AU2019242628A1 (en) 2018-03-26 2020-09-24 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
JP2023518419A (ja) * 2020-03-20 2023-05-01 クリア クリーク バイオ, インコーポレイテッド ブレキナルナトリウムの安定した多形性組成物ならびにその使用および製造方法
US12076315B2 (en) 2020-03-20 2024-09-03 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1653071A (zh) * 2002-03-18 2005-08-10 杏林制药株式会社 对耐药菌有效的10-(3-环丙基氨基甲基-1-吡咯烷基)吡啶并苯并噁嗪羧酸衍生物
CN1849316A (zh) * 2003-09-10 2006-10-18 杏林制药株式会社 7-(4-取代-3-环丙基氨基甲基-1-吡咯烷基)喹诺酮羧酸衍生物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
ZA87279B (en) 1986-01-17 1987-09-30 Chugai Pharmaceutical Co Ltd Method for production of stable nicorandil preparation
KR940000232B1 (ko) 1986-01-17 1994-01-12 쥬우가이세이야꾸 가부시끼가이샤 니코란딜 제제의 안정화 방법
JP2512302B2 (ja) 1986-03-19 1996-07-03 中外製薬株式会社 ニコランジル安定化製剤の製造方法
DE68913517T2 (de) 1988-12-28 1994-06-09 Taisho Pharma Co Ltd Verfahren zum verteilen des pressdrucks beim tablettieren.
JP2682353B2 (ja) 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
TW284688B (enExample) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2006111639A (ja) 1993-10-21 2006-04-27 Takeda Chem Ind Ltd 医薬用錠剤
JPH08175996A (ja) 1994-12-22 1996-07-09 Taiyo Yakuhin Kogyo Kk ニコランジル安定化固形製剤の製法
JP3119801B2 (ja) 1995-09-28 2000-12-25 武田薬品工業株式会社 ビタミン含有組成物の安定化方法
JPH10245335A (ja) 1997-02-28 1998-09-14 Dainippon Pharmaceut Co Ltd 圧力に不安定な薬物の打錠方法及びそれに用いられる湿潤顆粒
DE69905452D1 (de) 1998-03-03 2003-03-27 Daewoong Pharmaceutical Co Feuchtigkeitsstabile cefuroxim axetil enthaltende pharmazeutische zusammenstellungen
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
DE10048510A1 (de) 2000-09-29 2002-05-16 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
KR20030087009A (ko) 2001-02-27 2003-11-12 랜박시 래보러터리스 리미티드 세프포독심 프록세틸의 경구용 약학 조성물
US7219132B2 (en) 2001-03-30 2007-05-15 Space Systems/Loral Dynamic resource allocation architecture for differentiated services over broadband communication networks
EP1459739B1 (en) 2003-03-19 2008-01-02 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Non-hygroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids
RU2007104026A (ru) 2004-07-02 2008-08-10 Дайити Фармасьютикал Ко., Лтд. (JP) Содержащая хинолон лекарственная композиция
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
JPWO2006059716A1 (ja) 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
AR052559A1 (es) 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
SI1843754T1 (sl) 2005-01-26 2011-12-30 Lek Pharmaceuticals D.D. Novi farmacevtski sestavek, ki vsebuje kandesartan cileksetil kot lipofilno kristalinično snov
JP2006298811A (ja) 2005-04-20 2006-11-02 Taiyo Yakuhin Kogyo Kk ゲル化抑制製剤の設計
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2013145749A1 (ja) 2012-03-29 2013-10-03 杏林製薬株式会社 カプセル製剤
JP6062422B2 (ja) 2012-03-29 2017-01-18 杏林製薬株式会社 カプセル製剤
JP5700740B1 (ja) 2013-04-25 2015-04-15 杏林製薬株式会社 固形医薬組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1653071A (zh) * 2002-03-18 2005-08-10 杏林制药株式会社 对耐药菌有效的10-(3-环丙基氨基甲基-1-吡咯烷基)吡啶并苯并噁嗪羧酸衍生物
CN1849316A (zh) * 2003-09-10 2006-10-18 杏林制药株式会社 7-(4-取代-3-环丙基氨基甲基-1-吡咯烷基)喹诺酮羧酸衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Quinolones: structure-activity relationships and future predictions;G. S. TILLOTSON;《J. Med. Microbiol.》;19961231;第44卷;第320-324页 *
Stability Indicating Methods for the Determination of Some Fluoroquinolones in the Presence of Their Decarboxylated Degradates;Maissa Yacoub SALEM等;《Chem. Pharm. Bull.》;20061231;第54卷(第12期);第1625-1632页 *

Also Published As

Publication number Publication date
CA2910112C (en) 2021-02-16
JP5651812B1 (ja) 2015-01-14
EP2990038A4 (en) 2016-11-16
EP2990038B1 (en) 2019-11-20
JPWO2014174846A1 (ja) 2017-02-23
CA2910112A1 (en) 2014-10-30
CN105338982A (zh) 2016-02-17
JP2015078201A (ja) 2015-04-23
US20160067185A1 (en) 2016-03-10
JP6391436B2 (ja) 2018-09-19
US9603804B2 (en) 2017-03-28
EP2990038A1 (en) 2016-03-02
ES2768651T3 (es) 2020-06-23
WO2014174846A1 (ja) 2014-10-30

Similar Documents

Publication Publication Date Title
CN105338982B (zh) 固体药用组合物
JP7373491B2 (ja) 嚢胞性線維症を処置するための医薬組成物
CN105338981B (zh) 固体药用组合物
JP6759390B2 (ja) トホグリフロジンを含有する固形製剤及びその製造方法
JP6349306B2 (ja) 錠剤
JPWO2013145750A1 (ja) カプセル製剤
JP6050322B2 (ja) カプセル製剤
JP6018334B2 (ja) 固形医薬組成物
RU2822220C2 (ru) Фармацевтические композиции для лечения муковисцидоза
RU2822220C9 (ru) Фармацевтические композиции для лечения муковисцидоза
JPWO2016063544A1 (ja) 固形医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Patentee after: KYORIN PHARMACEUTICAL Co.,Ltd.

Address before: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Patentee before: Xinglin Holding Co.

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20231214

Address after: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Patentee after: Xinglin Holding Co.

Address before: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Patentee before: KYORIN PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right
CP03 Change of name, title or address

Address after: 3-7 Otemachi 1-chome, Chiyoda ku, Tokyo, Japan

Patentee after: KYORIN PHARMACEUTICAL Co.,Ltd.

Country or region after: Japan

Address before: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Patentee before: KYORIN PHARMACEUTICAL Co.,Ltd.

Country or region before: Japan

CP03 Change of name, title or address